|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NOL8 |
Gene summary for NOL8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NOL8 | Gene ID | 55035 |
| Gene name | nucleolar protein 8 | |
| Gene Alias | C9orf34 | |
| Cytomap | 9q22.31 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A6H8Z4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55035 | NOL8 | LZE2T | Human | Esophagus | ESCC | 2.34e-04 | 3.37e-01 | 0.082 |
| 55035 | NOL8 | LZE4T | Human | Esophagus | ESCC | 1.37e-13 | 3.88e-01 | 0.0811 |
| 55035 | NOL8 | LZE7T | Human | Esophagus | ESCC | 8.23e-11 | 3.83e-01 | 0.0667 |
| 55035 | NOL8 | LZE8T | Human | Esophagus | ESCC | 1.37e-02 | 1.12e-01 | 0.067 |
| 55035 | NOL8 | LZE20T | Human | Esophagus | ESCC | 3.11e-03 | 9.75e-02 | 0.0662 |
| 55035 | NOL8 | LZE24T | Human | Esophagus | ESCC | 1.58e-09 | 2.46e-01 | 0.0596 |
| 55035 | NOL8 | LZE21T | Human | Esophagus | ESCC | 3.80e-04 | 1.99e-01 | 0.0655 |
| 55035 | NOL8 | P1T-E | Human | Esophagus | ESCC | 1.21e-03 | 1.81e-01 | 0.0875 |
| 55035 | NOL8 | P2T-E | Human | Esophagus | ESCC | 6.99e-37 | 5.50e-01 | 0.1177 |
| 55035 | NOL8 | P4T-E | Human | Esophagus | ESCC | 3.84e-20 | 5.07e-01 | 0.1323 |
| 55035 | NOL8 | P5T-E | Human | Esophagus | ESCC | 2.29e-16 | 2.67e-01 | 0.1327 |
| 55035 | NOL8 | P8T-E | Human | Esophagus | ESCC | 4.68e-14 | 2.11e-01 | 0.0889 |
| 55035 | NOL8 | P9T-E | Human | Esophagus | ESCC | 2.56e-13 | 3.13e-01 | 0.1131 |
| 55035 | NOL8 | P10T-E | Human | Esophagus | ESCC | 1.25e-32 | 4.84e-01 | 0.116 |
| 55035 | NOL8 | P11T-E | Human | Esophagus | ESCC | 3.75e-10 | 5.52e-01 | 0.1426 |
| 55035 | NOL8 | P12T-E | Human | Esophagus | ESCC | 6.62e-26 | 4.18e-01 | 0.1122 |
| 55035 | NOL8 | P15T-E | Human | Esophagus | ESCC | 8.05e-14 | 2.32e-01 | 0.1149 |
| 55035 | NOL8 | P16T-E | Human | Esophagus | ESCC | 1.59e-16 | 2.90e-01 | 0.1153 |
| 55035 | NOL8 | P17T-E | Human | Esophagus | ESCC | 1.71e-08 | 3.78e-01 | 0.1278 |
| 55035 | NOL8 | P19T-E | Human | Esophagus | ESCC | 6.59e-05 | 4.13e-01 | 0.1662 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:003450418 | Esophagus | ESCC | protein localization to nucleus | 211/8552 | 290/18723 | 4.06e-21 | 6.60e-19 | 211 |
| GO:190257011 | Esophagus | ESCC | protein localization to nucleolus | 13/8552 | 16/18723 | 4.05e-03 | 1.62e-02 | 13 |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:001607212 | Liver | HCC | rRNA metabolic process | 193/7958 | 236/18723 | 1.26e-35 | 1.14e-32 | 193 |
| GO:000636421 | Liver | HCC | rRNA processing | 185/7958 | 225/18723 | 8.14e-35 | 6.45e-32 | 185 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:003450421 | Liver | HCC | protein localization to nucleus | 194/7958 | 290/18723 | 2.84e-17 | 2.85e-15 | 194 |
| GO:19025701 | Liver | HCC | protein localization to nucleolus | 13/7958 | 16/18723 | 1.84e-03 | 9.42e-03 | 13 |
| GO:002261320 | Oral cavity | OSCC | ribonucleoprotein complex biogenesis | 333/7305 | 463/18723 | 8.28e-48 | 5.24e-44 | 333 |
| GO:004225420 | Oral cavity | OSCC | ribosome biogenesis | 230/7305 | 299/18723 | 3.22e-41 | 6.80e-38 | 230 |
| GO:000636410 | Oral cavity | OSCC | rRNA processing | 172/7305 | 225/18723 | 1.57e-30 | 1.24e-27 | 172 |
| GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NOL8 | SNV | Missense_Mutation | c.2190N>A | p.Asp730Glu | p.D730E | Q76FK4 | protein_coding | tolerated(0.21) | benign(0.003) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| NOL8 | SNV | Missense_Mutation | c.1136G>A | p.Gly379Glu | p.G379E | Q76FK4 | protein_coding | tolerated(0.08) | benign(0.042) | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
| NOL8 | SNV | Missense_Mutation | rs373571114 | c.2234N>T | p.Ser745Leu | p.S745L | Q76FK4 | protein_coding | tolerated(0.28) | benign(0.054) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NOL8 | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Tyr | p.S361Y | Q76FK4 | protein_coding | tolerated(0.1) | benign(0.24) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NOL8 | SNV | Missense_Mutation | novel | c.522C>A | p.Asn174Lys | p.N174K | Q76FK4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A03P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | PD |
| NOL8 | SNV | Missense_Mutation | c.69C>A | p.Asp23Glu | p.D23E | Q76FK4 | protein_coding | tolerated(0.43) | possibly_damaging(0.625) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD | |
| NOL8 | SNV | Missense_Mutation | novel | c.2551N>G | p.Arg851Gly | p.R851G | Q76FK4 | protein_coding | deleterious(0) | benign(0.184) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| NOL8 | insertion | Nonsense_Mutation | novel | c.555_556insTAGTATACCTCCTTTGTTTAACACATGAAGAAA | p.Thr185_Ile186insTer | p.T185_I186ins* | Q76FK4 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| NOL8 | SNV | Missense_Mutation | novel | c.2746N>A | p.Leu916Met | p.L916M | Q76FK4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| NOL8 | SNV | Missense_Mutation | c.879N>C | p.Lys293Asn | p.K293N | Q76FK4 | protein_coding | tolerated(1) | benign(0) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |